CNS Summit 2017 Abstracts of Poster Presentations
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period. Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies. Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF Presenter: Chelsky D Affiliation: CSO, Caprion Biosciences, Inc., Montreal, Quebec, Canada Background/Objective: Early detection markers are critical for neurodegenerative diseases since substantial, irreversible damage to the brain occurs by the time of clinical diagnosis. Markers of disease progression are also important, as established clinical assessment tools can require a year or more to detect changes. Current efforts in our laboratory include developing such markers in Alzheimer’s, Parkinson’s, and Huntington’s diseases. Design: Candidate biomarkers were identified in the literature for each disease, and targeted metabolic response modifiers (MRM) mass spectrometry assays were assembled. In the case of Huntington’s disease, very few candidate markers were known in the literature, so a label-free liquid chromatography–tandem mass spectrom...
Publication date: November–December 2020Source: Heart &Lung, Volume 49, Issue 6Author(s): Linda Clements, Susan K. Frazier, Debra K. Moser, Terry A. Lennie, Misook L. Chung
Publication date: Available online 22 September 2020Source: Heart &LungAuthor(s): Silvio A. Ñamendys-Silva
Publication date: Available online 22 September 2020Source: Social Science &MedicineAuthor(s): Yukiko Asada, Michel Grignon, Jeremiah Hurley, Susan Kirkland
Publication date: 1 January 2021Source: Personality and Individual Differences, Volume 168Author(s): Feizhong Zheng, Wenting Wu, Lijing Wang, Arlette J. Ngoubene-Atioky, Li Chen
Publication date: November 2020Source: Learning and Motivation, Volume 72Author(s): I-Fan Liu
Publication date: Available online 22 September 2020Source: International Journal of PsychophysiologyAuthor(s): Chiara Massullo, Giuseppe Alessio Carbone, Benedetto Farina, Angelo Panno, Cristina Capriotti, Marta Giacchini, Sérgio Machado, Henning Budde, Eric Murillo-Rodríguez, Claudio Imperatori
US drugmaker Johnson&Johnson says the vaccine could be available for use by early 2021 if proven safe, effective. In the next phase J&J will enroll up to 60,000 volunteers across three continents and study safety and efficacy of a single vaccine dose.
Johnson&Johnson has advanced its one-shot COVID-19 vaccine into phase 3 testing. The National Institute of Allergy and Infectious Diseases describes this as the fourth candidate to reach this stage.Medscape Medical News
Getting the right care in a timely manner is important in medical emergencies. In the event that you or a loved one suffers a stroke, time is especially critical. “In the event of a stroke, a delay of only 15 minutes in treatment greatly decreases your chances not only of making a full recovery, but also being able to walk or live independently, and in many cases, of survival,” says Christopher Zammit, MD, a critical care specialist and emergency physic ian with TriHealth, which offers a network…
CONCLUSION: In a NHP ARS model, sargramostim administered starting at 48 h post-radiation was effective to improve survival, while beneficial hematological effects were observed with sargramostim initiated up to 120 h post exposure. PMID: 32960660 [PubMed - as supplied by publisher]
More News: Academia | Addiction | Advertising | African Health | AIDS Vaccine | Alcoholism | ALS | Alzheimer's | Anxiety | AstraZeneca | Austria Health | Biomedical Engineering | Bipolar | Brain | Bupropion | Calcium | Canada Health | Child Abuse | Child Development | Children | Classrooms | Clinical Trials | Computers | Concussion | Cyclobenzaprine | Databases & Libraries | Dementia | Denmark Health | Depression | Disability | Education | Epilepsy | Generalized Anxiety Disorder (GAD) | Genetics | Grants | Health Insurance | HIV AIDS | Insurance | International Medicine & Public Health | Internet | Laboratory Medicine | Lamictal | Learning | Malaria | Malaria Vaccine | Mania | Men | Mexico Health | Multiple Sclerosis | Nanotechnology | Neurology | Neuroscience | Nicotine | Occupational Health | Pfizer | Psychiatry | Psychology | Rosemary | Schizophrenia | Science | Sexual Dysfunction | Sleep Disorders | Sleep Medicine | Social Anxiety Disorder | Sodium | Sodium Chloride | Sports Medicine | Statistics | Stroke | Study | Suicide | Sweden Health | Taiwan Health | Teaching | Training | Tuberculosis | Universities & Medical Training | USA Health | Vaccines | Wellbutrin | WHO | Women | Yale